OCX OncoCyte Corp

USD 2.98 -0.02 -0.6004
Icon

OncoCyte Corp (OCX) Stock Analysis and Price Targets

COMMON STOCK | Diagnostics & Research | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.98

-0.02 (-0.60)%

USD 0.02B

1.77K

USD 3.30(+10.74%)

N/A

Icon

OCX

OncoCyte Corp (USD)
COMMON STOCK | NSD
USD 2.98
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.02B

N/A

USD 2.98

OncoCyte Corp (OCX) Stock Forecast

Show ratings and price targets of :
USD 3.30
(+10.74%)

Based on the OncoCyte Corp stock forecast from 2 analysts, the average analyst target price for OncoCyte Corp is USD 3.30 over the next 12 months. OncoCyte Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of OncoCyte Corp is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, OncoCyte Corp’s stock price was USD 2.98. OncoCyte Corp’s stock price has changed by -2.93% over the past week, +0.68% over the past month and -46.40% over the last year.

No recent analyst target price found for OncoCyte Corp
No recent average analyst rating found for OncoCyte Corp

Company Overview OncoCyte Corp

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma...Read More

https://oncocyte.com

15 Cushing, Irvine, CA, United States, 92618

75

December

USD

USA

Adjusted Closing Price for OncoCyte Corp (OCX)

Loading...

Unadjusted Closing Price for OncoCyte Corp (OCX)

Loading...

Share Trading Volume for OncoCyte Corp Shares

Loading...

Compare Performance of OncoCyte Corp Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for OCX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To OncoCyte Corp (Sector: Diagnostics & Research )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO
Thermo Fisher Scientific Inc +10.55 (+1.85%) USD219.76B 37.30 22.26

ETFs Containing OCX

Symbol Name OCX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About OncoCyte Corp (OCX) Stock

Based on ratings from 2 analysts OncoCyte Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on OCX's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for OCX is USD 3.30 over the next 12 months. The maximum analyst target price is USD 3.6 while the minimum anlayst target price is USD 3.

Unfortunately we do not have enough data on OCX's stock to indicate if its overvalued.

The last closing price of OCX's stock was USD 2.98.

The most recent market capitalization for OCX is USD 0.02B.

Based on targets from 2 analysts, the average taret price for OCX is projected at USD 3.30 over the next 12 months. This means that OCX's stock price may go up by +10.74% over the next 12 months.

We can't find any ETFs which contains OncoCyte Corp's stock.

As per our most recent records OncoCyte Corp has 75 Employees.

OncoCyte Corp's registered address is 15 Cushing, Irvine, CA, United States, 92618. You can get more information about it from OncoCyte Corp's website at https://oncocyte.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...